(PDF) P1.04-27 Safety of Immunotherapy in Non-Small Cell

P1.04-27 Safety of Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) in the Real-Life Setting: A Single-Institution Experience From Argentina

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.742

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

P1.04-21 the Utility of PD-L1/CD8 Dual Immunohistochemistry for Prediction of Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.04-25 the Implication of Frameshift Mutation Burden in Neoantigen and Immune Cell Landscape in Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology

Respiratory Medicine

English

OA 17.05 IFCT-1502 CLINIVO: Real-Life Experience With Nivolumab in 600 Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology

Respiratory Medicine

English

Checkpoint Inhibitors in Squamous Non-Small Cell Lung Cancer (NSCLC)

Open Access Journal of Oncology and Medicine

English

P1.04-03 Suppressive Immune Cell Profiling in Patients With Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Latest Immunotherapy Methods in Non-Small Cell Lung Cancer Treatment

Juntendo Medical Journal

English

Quantifying the Benefit of Non-Small-Cell Lung Cancer Immunotherapy

English

P3.08-02 Oligometastatic Non Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy (SBRT), a Single Institution Experience

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.04-19 Neutrophil-To-Lymphocyte and Platelet-To-Lymphocyte Ratios Predict Survival After Immunotherapy in Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English